Rebecca Sorber1, Michael J Osgood1, Christopher J Abularrage1, James H Black1, Ying Wei Lum2. 1. Division of Vascular Surgery and Endovascular Therapy, The Johns Hopkins Hospital, Halsted 668 600 N Wolfe Street, Baltimore, MD, 21287, USA. 2. Division of Vascular Surgery and Endovascular Therapy, The Johns Hopkins Hospital, Halsted 668 600 N Wolfe Street, Baltimore, MD, 21287, USA. ylum@jhmi.edu.
Abstract
PURPOSE OF REVIEW: This review provides an overview of the current literature surrounding the medical and surgical treatment of aortic graft infection with particular focus on the role of endovascular aortic grafts in the changing demographics and management of these infections. RECENT FINDINGS: Definitive therapy for aortic graft infection continues to include parenteral antibiotics and surgical explantation and revascularization procedures, which are historically vast operations and sources of significant operative stress. Surgical management has evolved to include more options for infection resistant in situ conduits, attempts at partial explantations, and use of endovascular therapy to temporize the urgent sequelae of these infections, such as aortoenteric fistula. Aortic graft infection continues to be a significant and morbid complication of graft placement even with the advent of endovascular therapy, and its treatment will only increase in difficulty as a more frail population has gained access to complex aortic repair. In the future, more flexible revascularization and partial explantation options are keys, along with long-term suppressive antibiotics where appropriate.
PURPOSE OF REVIEW: This review provides an overview of the current literature surrounding the medical and surgical treatment of aortic graft infection with particular focus on the role of endovascular aortic grafts in the changing demographics and management of these infections. RECENT FINDINGS: Definitive therapy for aortic graft infection continues to include parenteral antibiotics and surgical explantation and revascularization procedures, which are historically vast operations and sources of significant operative stress. Surgical management has evolved to include more options for infection resistant in situ conduits, attempts at partial explantations, and use of endovascular therapy to temporize the urgent sequelae of these infections, such as aortoenteric fistula. Aortic graft infection continues to be a significant and morbid complication of graft placement even with the advent of endovascular therapy, and its treatment will only increase in difficulty as a more frail population has gained access to complex aortic repair. In the future, more flexible revascularization and partial explantation options are keys, along with long-term suppressive antibiotics where appropriate.
Authors: Arman Kilic; Ashish S Shah; James H Black; Glenn J R Whitman; David D Yuh; Duke E Cameron; John V Conte Journal: J Thorac Cardiovasc Surg Date: 2013-08-28 Impact factor: 5.209
Authors: Gustavo S Oderich; Thomas C Bower; Jan Hofer; Manju Kalra; Audra A Duncan; John W Wilson; Stephan Cha; Peter Gloviczki Journal: J Vasc Surg Date: 2011-01 Impact factor: 4.268
Authors: M Liberatore; A P Iurilli; F Ponzo; D Prosperi; C Santini; P Baiocchi; L Rizzo; F Speziale; P Fiorani; A C Colella Journal: J Nucl Med Date: 1998-05 Impact factor: 10.057
Authors: M van Zitteren; T J van der Steenhoven; D H C Burger; D P van Berge Henegouwen; J M M Heyligers; P W H E Vriens Journal: Eur J Vasc Endovasc Surg Date: 2011-03-04 Impact factor: 7.069
Authors: Adam W Beck; Erin H Murphy; Jennie A Hocking; Carlos H Timaran; Frank R Arko; G Patrick Clagett Journal: J Vasc Surg Date: 2007-12-03 Impact factor: 4.268
Authors: Matthew R Smeds; Audra A Duncan; Michael P Harlander-Locke; Peter F Lawrence; Sean Lyden; Javariah Fatima; Mark K Eskandari Journal: J Vasc Surg Date: 2016-02 Impact factor: 4.268